Abstract. The accelerating change and innovation in the biotechnology sector has increased the pressure on firms to challenge the traditional "Mode-one" approach to manage and transfer scientific and technological knowledge from university research centres. Firms, and universities, are increasingly adopting new and more complex approaches for the management and transfer of such knowledge and related innovations. This paper illustrates and conceptualises these emerging approaches from a strategic and knowledge management perspective. In so doing, this chapter draws from key theoretical contributions from the academic literature in order to explain the emerging management and transfer processes, which are identified in five specific University-Industry collaborations in the Biotechnology Sector in the United Kingdom. The paper integrates these transfer processes into a wider strategic framework, which would enable firms to successfully manage and internalise public scientific and technological knowledge.
Introduction
A firm's long-term success and survival increasingly depends less on particular products and more on an organisation's distinctive capabilities to develop, share and utilise scientific and technological knowledge (Coombs, 1996; Bertels & Savage, 1998) . There is also a widespread agreement that a key factor for sustained innovation and economic success lies in individual firms ability to foster collaboration between academia and industrial research (Faulkner, 1995; Kodama & Branscomb, 1999; Santoro & Chakrabarti, 2001) .
These issues are of major relevance in terms of the strategic management of knowledge flows between public sector research base and private firms. For this reason, this paper devises a new strategic and knowledge management framework that would assist biotechnology and pharmaceutical firms to manage and internalise public scientific and technological knowledge from universities.
In so doing, the paper uses key findings from a recent university-industry links study for the biotechnology and ICT industry in the United Kingdom (Cox et al., 2000) . This study was part of a wider study investigating the future scenario of research in the UK, which was commissioned to the University of Using qualitative information from interviews the links between science base and industry in the Biotechnology industry are examined, and five case studies selected: Centre for Process Systems Engineering, Imperial College; SensAlyse Ltd., Manchester Science Park; Amersham Pharmacia Biotech; SmithKline Beecham (now GlaxoSmithKline); and AstraZeneca. Martin and Salter's (1996) framework has been chosen as a guidepost for the analysis of case studies: (i) technological problem solving; (ii) creation of new firms; (iii) new instrumentation and methodologies; (iv) skilled graduates; and (v) professional networks. There is a major distinction, however, between Martin and Salter's framework and the framework proposed here. The five dimensions are not treated merely as benefits or lineal "Mode one" interactions. They are conceptualized as processes with dynamic characteristics. This difference in conceptualization is, we belief, aligned with the emergent "Mode two" of knowledge production. This new process conceptualization and cases, should help to illustrate the complex nature of key inter-organisational interactions involved in knowledge transfer between industry and academia.
A Review of Models of Interaction between Industry and the Science Base in the UK
There is a large and detailed literature on the topic of linkages between industry and the science base. A recent annotated bibliography from the British Library provides a guide to some of the newer material with a UK slant (Stewart, 1999) . The empirical situation is comprehensively described by Howells et al. (1998) . Among the most influential writings in recent years is the volume by Gibbons et al. which argued that there has been a transformation from traditional knowledge, called "Mode one", generated within a disciplinary, primarily cognitive context, to "Mode two" knowledge created in broader transdisciplinary social and economic contexts and carried out primarily in the context of application (Gibbons et al., 1994; Gibbons, 2000) . This much-cited work has very clear implications for how we look at the issue of linkages:
". . .the notion of technology transfer has to be reconsidered. It cannot any more be understood as a transmission of knowledge from the university to the receiver easily and usually with almost no follow up. Instead it is no longer like a relay race, in which the baton is passed cleanly and quickly from one runner to the next. Technology transfer looks more like a soccer game in which the university is a member of a team. To score it needs the aid of all its team mates. The ball is passed back and forth among the players who may include businesspeople, venture capitalists, patent attorneys, production engineers, and many others in addition to the university faculty. This is why it has been suggested that technology interchange is a more appropriate phrase than technology transfer." (Gibbons et al., 1994:87) A growing understanding of the interactive nature of science-industry links has been a feature of the best analyses in the literature for very many years. Table 1 summarises key findings form our literature review. In the first study of its kind, by Carter and Williams as long ago as 1957, the authors were already detecting that scientific publication was a medium, which would not reach the great majority of firms. They stressed the importance of communication networks, informal contacts and what would today be called intermediaries. The next major milestone in unraveling the linear model was the work by Langrish et al which, on the basis of extensive casestudies, found that scientific breakthroughs leading to radical new products or processes were the exception rather than the rule, with industry laying much greater stress on provision by universities of techniques and trained people.
Building on this work was a framework developed by Gibbons and Johnston and extensively reworked in an up to date context by Faulkner and Senker. The latter's publication is of particular interest here because it has two of three case studies on knowledge transfer in biotechnology and parallel computing. The framework involved, in summary, the use by industry of theories, procedures, skills and instrumentation. A sharp contrast was found in the usage made of science and technology inputs, with biotechnology being the only field where the science base is more significant as a source than other forms and exhibiting the highest levels of formal linkage and literature use.
The authors point out that linkage is geared to take advantage of new knowledge and techniques as they arise, since existing knowledge is codified or transferred into firms by recruitment. In parallel computing the level of formal linkage is found to be much lower, with supply chain links dominating as the source of external information. There is a high reliance on personal contacts, reflecting difficulties of codification of knowledge. Formal linkages are also seen to have been inhibited by the presence of large numbers of small firms.
To conclude this very short review, we refer to an influential study carried out by SPRU for HM Treasury, which examined The Relationship Between Publicly Funded Basic Research and Economic Performance. Itself a literature review, this review concluded that there were six different types of benefit from basic research among which only a comparatively small proportion of benefits flow is in the form of new useful knowledge that is directly incorporated in new products or processes. The full list, which incorporates all of the items mentioned in the previous references, is as follows:
• Basic research as a source of new useful information.
• The creation by basic researchers of new instrumentation and methodologies.
• Skills developed by those engaged in basic research (especially graduate students) which yield economic benefits when individuals move from basic research carrying codified and tacit knowledge.
• Participation in basic research to gain access to networks of experts and information.
• The fact that those trained in basic research may be particularly good at solving complex technological problems.
• The creation of spin-off companies.
Case Studies
The cases outlined here are drawn from a universityindustry links study for the biotechnology and ICT industry in the United Kingdom (Cox et al., 2000) . This study was part of a wider study investigating the future scenario of research in the UK, which was commissioned to The Centre, started in 1989, is dedicated to carrying out interdisciplinary research in process systems engineering. The Centre involves academic faculty from several departments at Imperial College (IC) and University College London (UCL). The Centre addresses the gap between fundamental concept development and its application in Industry. Its research is focused on the development of methodologies for modelling, design, control and operations management of process plants. The Centre has been deeply involved with Industry in identifying technological problems and developing theories and technologies that could address these problems. In few years down the line there has been a fair amount of technology, which has now proved itself in the early software prototypes as new ways of addressing new technological problems. The type of technology the Centre develops deal with how to design a new plant of the type such as pharmaceutical plant, chemical plant, polymers, food processing, oil and gas, the called process industries.
The College was not in a position to follow up exploitation and came with the idea of setting up a company to take up the technology and software packages. The spin-off company has a strong link with Imperial college but also is developing links with other Universities for similar sources and not to be completely dependent on a single source. The reason the centre created this organisation instead of licensing the technology was because this link needs to be strong. Technology moves very fast in this area and to stay at the forefront there is the need to have an intimate link with fundamental R&D, and to have close link with the technological problems the research at University needs to be aware of. At the research site, the work done at the University is developing new methods and trying out prototypes the first time. What the company does is packaging the software to a commercial standard and offers it to companies that want to have proper output. The technology is packaged into something useful for a non-PhD. An average engineer can sit down and use the tools. The typical users of the technology are R&D organisations, which are involved in new product and process development, and operating companies which are involved in optimising plants. These are manufacturing companies like Unilever and ICI, which seek to improve competitiveness by designing better processes.
The design and optimisation of plants involve complex set of activities and requires knowledge on engineering phenomena, mathematical modelling, computing science, and control and automation. The technology developed at the Centre can hide all this complexity from the end-user, dealing with problems of a large scale and with hundred of thousand equations. The technology has been applied in the oil industry, cereal plants, yoghurt plants, and breweries. Typically the return on investment when designing a new plant ranges from 20% to 25% savings on the capital investment. In the operational side, 20% savings on operating cost or improving profits by better scheduling a plant is common. Other things which are harder to measure but no less important are the advantages of designing a new product faster. The return can be very high specially if a company can save in building a prototype, because to go from chemistry bench lab to the large-scale plant it would be necessary to build all the intermediate steps to be sure everything will work. This can be avoided by using modelling and simulation tools.
SensAlyse Ltd., Manchester Science Park, Manchester
Originally the company was conceived as Sensor Solutions, when it was established in 1993. The specific area of activity is in the field of biosensor technology. The company started off as a services business providing contract development for third party companies that needed to use specialist expertise to develop front-end analytic equipment. Part of the current strategy of SensAlyse is to develop reliable analytical systems which are based on biosensor technology, and to transfer, or to finish transferring the technology into manufacturing, so the company can produce saleable devices that meet the market needs of the wine and beer industries. The company was derived from the Department of Clinical Biochemistry in Hope Hospital in Salford under the leadership of Professor Vadgama. Sensalyse employs seventeen staff most of them graduates. Sensalyse employs six PhDs, including the technical director who is a biotechnologist and did his PhD at Manchester University. Initially when it was established, Manchester University looked after the management of the company and also provided market research, financial services, and general management support. The company has a strong intellectual property portfolio consisting of 18 patents held by the University of Manchester, in the hands of its holding company, formerly VUMAN. A further 12 patents are owned by SensAlyse, which were transferred to the company after the management buyout. SensAlyse has a good proven record of achievement in scientific technology areas. The company has had a number of awards, LINK awards, and SMART awards. SensAlyse has participated in a successful joint European venture, and has developed partnerships with firms in Ireland and France.
During the year 2000, SensAlyse has launched a device to detect the alcohol level in wine and beer. Currently wine or beer producers take their samples to an external lab and have to wait a minimum of three days to obtain the results and this is expensive. Larger producers have their own laboratories and expensive equipment to purchase and maintain, as well as having to keep staff on the payroll. SensAlyse is taking all this technology down to the production area and delivering results very rapidly, in less than three minutes. Obtaining the results rapidly is important because that enables taking remedy actions swiftly. SensAlyse calls this framework point-of-activity testing, which implies doing the test where the activity is undertaken at the production line. Product differentiation lies in the portability of all their instruments for detecting alcohol. In addition, Sensalyse has developed biosensors for third party companies for diagnostic tasks in the clinical sector.
Amersham Pharmacia Biotech
Amersham Pharmacia Biotech is the life sciences business of Nycomed Amersham plc. Amersham Pharmacia Biotech was formed after the merger of Amersham Life Sciences and Pharmacia Biotech in 1997. Amersham has its origins in the 1940s. The company has 675 scientist world-wide, including 200 in the UK. Amersham Pharmacia Biotech supplies two types of products. One is research tools, reagents and systems for academic research in universities, hospital research units and pharmaceutical companies. The company provides reagents, hardware, software; instruments for the drug discovery process. Other parts of the business consist of bioprocessing; chromatography-based separation of biological molecules and production of vaccines. The company provides hardware, resins and columns to assist purification processes by chromatography for large scale production systems. The company also manufactures laboratory chromatography equipment for basic research.
Amersham Pharmacia Biotech has a long term record of collaboration with academic research centres and small biotech firms. The company develops and commercialises technology based on invention and basic research from Universities in the UK, Europe and USA, in addition to in-house innovation. Research collaboration with UK Universities includes Oxford, Cambridge, Manchester and Cardiff. For example, the company has a long-standing relationship, over ten years, with the Laboratory of Molecular Biology at Cambridge and more recently with the Sanger Centre, which is funded by the Wellcome Trust. More specifically, the Sanger Centre invented an instrument to support DNA hybridisation. Amersham Pharmacia Biotech has developed this as a commercial product, which is now used in academic and pharmaceutical research. This new instrument allows the automation of the DNA hybridisation process. Researchers have traditionally carried out this process manually using a series of microscope slide based DNA chips, adding reagents, incubating, washing, and repeating the process again. This process is labour intensive, and is time consuming and subject to human error and variations.
The new instrument allows the laboratory to automate the whole slide process cycle. Researchers have traditionally carried out this process manually using a series of microscope slide based DNA chips, adding reagents, incubating, washing, and repeating the process again. This process is labour intensive, and is time consuming and subject to human error and variations. This benefits the academic researchers with higher productivity and reproducibility. The experimental process supported identifies which genes are used in which cells and at what time and allows comparisons of normal cells with those that are diseased or damaged by toxic chemicals. It allows a better understanding of biological and medical processes.
The new instrument in this case was not leading edge technology but solved a particular technological problem for the biotechnology industry. The collaboration with Sanger allowed Amersham Pharmacia Biotech to develop an instrument more quickly. This instrument also helped to achieve stronger product differentiation apart from the automation of the manual process. A continuous research collaboration with Manchester University is exploring ways to increase the sensitivity of fluorescence detection methods for life science research applications using novel instrumentation and chemistry approaches.
GlaxoSmithKline
SmithKline Beecham, now merged with Glaxo Wellcome to form GlaxoSmithKline, one of the world's leading healthcare companies. Over 52,000 people contribute to discovering, developing, manufacturing and marketing pharmaceuticals, vaccines, over-the-counter medicines and health related consumer products in over 160 countries. SmithKline Beecham is a highly professional, researchbased pharmaceutical firm. The company spends between 10% and 15% of its annual turnover on R&D. The majority of R&D efforts in Europe are concentrated in the UK at the New Frontiers Science Park in Harlow. The company has 2,500 R&D staff in the UK and 5,300 worldwide. Pharmaceutical R&D is concentrated in four therapeutic areas: anti-infectives, cardiopulmonary, inflammation & tissue repair and oncology, and neuroscience.
GlaxoSmithKline offers industrial placement opportunities for undergraduate and postgraduate students in all the key functions within Pharmaceutical Research & Development. Areas for research include discovery chemistry, neuroscience, biotechnology & genetics, microbial & cell culture sciences, pharmacological sciences & functional gene analysis, molecular screening technologies, drug metabolism and & pharmacokinetics, and clinical pharmacology. In addition, GlaxoSmithKline offers industrial placements in biostatistics and bioinformatics. An industrial placement in any of these areas provides a good overview of the research process in a major multinational pharmaceutical company like GlaxoSmithKline. This also serves to illustrate the necessity of interdisciplinary interaction and teamwork in identifying the next generation of therapeutic agents. GlaxoSmithKline has a steady graduate intake to provide "base" skills for the company and has been very successful under EUFP5 Marie Curie Industry Host Fellowship Programme. The company was awarded 20 postdoctoral scientists via this route. In 1999, the number of CASE PhD studentships, in collaboration with 4 Research Councils, was 165 and GlaxoSmithKline also had 145 industrial placement students. The percentage of total workforce that is graduates or PhD's is 69%. The percentages in science, engineering and medical are: science 84%, engineering 0.75%, and medical 2.5%
There are, however, perceived deficiencies especially in undergraduate courses, with not enough practical work and hence a general decline in laboratory experience. This causes problems for companies like GlaxoSmithKline. In the past, industrial placement students would be given a project immediately they started working in the company because they were properly trained; now they need additional training for 2-3 months because they have limited practical experience and as a result GSK only take students on 12 month placements. Universities are simply taking on too many students who are not being properly trained; they need more practical experience.
There has been a shortage of good chemistry graduates over the last few years in the UK as the universities went onto a 4 year undergraduate course, because of this shortage GlaxoSmithKline started recruiting from Germany, France, Italy and Spain. Often the overseas recruits are seen as having better practical training than the UK equivalent.
If the company wants to expand rapidly in a specific research area, GlaxoSmithKline will "buy in" a whole team from a university. This will allow GlaxoSmithKline to get up to speed rapidly in a new area. For example, the company recruited key staff from the Genetics Department of University of Cambridge to gain functional Genomics expertise.
AstraZeneca
The research work carried out at AstraZeneca is mainly discovery work, but not fundamental work, into the causes of cancer. The way that AstraZeneca do their research is to identify molecular targets. The most important type of collaboration with the University is fundamental research. These are collaborations that try to expand the strategic horizon of the company and to see new approaches to drug discovery and include new developments and implementation of new technologies. They incorporate discovery of new targets and approaches to those targets. There is a real opportunity in fundamental research and it is also much easier to publish. Publishing can be difficult sometimes in applied research (e.g., specific techniques) and that is an impediment to the university scientists. Collaboration in fundamental research is the most important and that should be put the most emphasis.
According to AstraZeneca's Head of Project Evaluation:
"The relationship between the company and universities falls in three categories. The first one is the exchange of human talent, recruiting graduates and postgraduates and also sometimes attracting whole teams of researchers and accommodating them into our structure. This is supplemented by fluid networks of scientists and academics collaborating in numerous joint research projects and publications. Thirdly, collaboration with new biotechnology firms which has sprung off universities. This is becoming an important issue for large pharmaceutical companies like us, with some companies outsourcing up to sixty or seventy percent of their research and development."
In the UK, AstraZeneca works in collaboration in cancer research and appetite control with the University of Manchester. Professional networks are one of the benefits of the relationship with Manchester University. These are however intangibles and AstraZeneca scientists network with people in a variety of different ways. There are other significant collaborations in the cancer research field with the Institute of Cancer Research at the Royal Marsden Hospital in London, and with the University of Newcastle, where there is a major program on tumour progression metastasis.
AstraZeneca has collaborated in cancer research with the University of Manchester since 1987. At that time the company gave £1.5 to a new research group at Manchester University working in areas of interest to AstraZeneca. The group employed five Fellows and was envisaged as a centre of excellence. The Fellows could also apply for additional UK funding from elsewhere and did in fact achieve additional funding. The AstraZeneca contribution proved helpful in the success of securing additional funds. The money AstraZeneca contributed could all have gone to an existing centre of excellence but AstraZeneca wanted a new centre to be able to ensure the research being carried out was of interest to them. Networking was one of the values of this collaboration.
A new research group was set up 1994 and over the last five years the young scientists involved have built a good group working in programme cell death at Manchester University. They have developed technology and understanding which is of benefit to AstraZeneca. Collaboration is also a very rich source of new talent to the company. Bringing in people is much better than trying to recruit from an advert and this is a facet of networking. During the 5 years additional post-doctoral researchers have been employed at the University and one is now working as a team leader at AstraZeneca. AstraZeneca believe they have a very good relationship with Manchester University and a network of people who they can talk to and interact with, who provide them with the science base for their medicines discovery.
AstraZeneca tries to identify the best people in the world, and particularly in Europe and the UK with whom the firm can collaborate. Opportunities for collaboration are identified through the network, this helps the company recruit the best people, find out what they are doing and evaluate the potential benefits for AstraZeneca. For example, if the company recruits a scientist from the laboratory on cancer research at Manchester University, then she/he is likely to have good contacts with that department and be able to point out advantages and skills in that laboratory. There are areas where AstraZeneca recognises the need to collaborate because the company may not have the skills internally.
Academic collaboration generates know how and potential new targets for AstraZeneca. Outputs and effects emerging from the collaborative research include knowledge on fundamental biological processes, new techniques and methods, and dissemination through conferences, publications, workshops and seminars. The advantage to university academics from the collaboration is that they are given the opportunity to understand how large companies go about the process of drug discovery and to see at first hand what is required. This puts them in a better position to write a business case if they decide they want to participate in the joint exploitation of the technology.
Devising a Strategic Framework to Manage Knowledge Transfer between University and Industry
The view of organizations as an agent of knowledge transfer, and the increasing strategic importance of the interrelationship between universities and biotechnology firms, highlights the need to devise a management frameworks based on the strategy and knowledge perspective (Coombs, 1996; Sanchez & Aime, 1997; Kodama & Branscomb, 1999; Miranda Oliveira, 1999; Swan et al., 1999; Santoro & Chakrabarti, 2001 ). Previous attempts to study the interrelationship between universities and high-tech firms have tended to focus on the inputs and outputs, rather than the actual processes of interaction as the unit of analysis (Faulkner & Senker, 1995; Martin & Salter, 1996; MeyerKrahmer & Schmoch, 1998) . A strand of innovation studies has indeed focused on the coordination mechanisms that facilitate innovation networks. These studies, however, generally have a regional or national scope in context to a particular technology or industry, and often the university-firm interface becomes blurred and undefined.
More recently, a new breed of innovation studies have started to give attention to internal core competences, such as internal skills, capabilities, organizational routines; and the relationships and knowledge flows within organizations (Peña, 2002; Verhaeghe & Kfir, 2002; Collinson & Gregson, 2003; Lindsay et al., 2003) . For instance, Verhaeghe & Kfir (2002) studied a sample of 114 managers in technology-based organisation in South Africa, and developed a framework to manage innovation practices used in the sampled organisations. The main analytical measures used in this study were: leadership, resourcing innovation, creativity, teamwork, technology transfer and acquisition, innovation performance, and scientific and commercial networking. An important goal of this study was to provide a tool for assisting a firm in assessing the required elements for successful innovation.
Another relevant pool of knowledge can be found in the strategic management literature, with studies focusing on inter-firm alliance formation, knowledge transfer and performance (Koza, 1998; Larsson, 1998; Pangarkar, 2003) . These studies, however, tend not to focus on the university-firm boundary, but on commercial enterprises.
This paper, therefore, devises a strategic knowledge management framework for the pharma and biotech industry, based on the conceptualization of the case studies. This framework is based on two dimensions: (i) inter-organisational knowledge-transfer processes; and (ii) organisational capabilities. Figure 1 tries to illustrate the relationship of these two dimensions with the broader policy context. All of these are, the author believes, key dimensions for enabling the required strategic and organisational development of pharmaceutical and biotechnology firms. The policies and initiatives promoting university-industry linkages and IPR regime, which also influence these knowledge transfer process, are not the main focus and will be discussed briefly within the scope of the present paper.
The increasing importance of inter-organisational links in the strategy and R&D literature put the case forward to focus on the processes promoting universityindustry links (Albertini & Butler, 1995; Staropoli, 1998; Henderson et al., 1999) . Given the intangible nature of knowledge in organizations, knowledge development will tend to occur at random and be unsystematic. To avoid this situation of uncertainty, pharmaceutical firms should establish the appropriate strategic framework to manage the processes for knowledge transfer. Knowledge transfer processes are necessary for stimulating wider cooperation between university and industry (Blacker et al., 1998; Salazar et al., 2003a and 2003b) . Knowledge management strategies should, therefore, be focused on strengthening inter-organisational processes and building core organisational capabilities so that knowledge is consistently and strategically developed.
Martin and Salter's framework was chosen as a guidepost for the analysis of the case studies: (i) technological problem solving; (ii) creation of new firms; (iii) new instrumentation and methodologies; (iv) skilled graduates; and (v) professional networks. There is a major distinction, however, between Martin and Salter's framework and the framework proposed here. dimensions are not treated merely as lineal "Mode one" interactions or benefits; they are conceptualised as processes with dynamic characteristics. This difference in conceptualisation is, we belief, aligned with the emergent "Mode two" notion of knowledge production. This new process conceptualisation and cases should help to illustrate the complex nature of key interorganisational interactions involved in knowledge transfer between industry and academia. The first case study has illustrated that fundamental and interdisciplinary research from Universities contributes directly to technological problem solving in the biotech industries. The fundamental and interdisciplinary research pursued at the Centre for Process Systems Engineering at Imperial College has been successfully transferred to industry through the development and exploitation of numerical models and software packages. This knowledge and technology enables biotech firms to better understand and innovate their manufacturing processes and plants. Critical to this success is the strong linkage between Imperial College and industrial partners through the Centre and its spin-off company. The Centre was not in a position to follow up exploitation and came with the idea of setting up a company to take up the technology. This new organisation, which can be conceptualised as an intermediary structure, 1 allowed the University to have close link with the technological problems the researchers at the Centre need to be aware of. In the second case study, the company was derived from a University Hospital under the leadership of a senior scientists.
Valuable technological knowledge has been transferred to Sensalyse through the recruitment of postdoctoral graduates, as well as patents from early scientific discoveries in clinical biochemistry from the University of Manchester.
2 This close collaboration has enabled Sensalyse to develop innovative products to support the management of manufacturing processes of wine and beer industries and will also allow the company to become an important player in this niche market world-wide. This relationship, however, needs to be strengthened and supported, particularly in the management and maintenance of the patent portfolio to ensure long-term success.
In the third example, close research collaboration with basic research gives Amersham Pharmacia Biotech the opportunity to acquire scientific knowledge and devise new ways to carry out drug research more effectively. A major management challenge was how to embody tacit knowledge into forms that are more effectively shared and exploited. Close collaboration with university allows the firm the application of fundamental research into the development of new instruments and methodologies.
3
The evidence from the fourth case shows that GlaxoSmithKline is a major employer of graduates and postgraduates from the science-base in the UK. An industrial placement in any of the drug discovery and development areas provides a good overview of the research process in a major multinational pharmaceutical company like GSK. This also serves to illustrate the necessity of interdisciplinary interaction and teamwork in identifying the next generation of therapeutic agents. No specific technological knowledge is important, but leadership research skills, imagination and creativity, which are intrinsic characteristics of "T-shaped" skills. T-shaped skills, are both very deep (the stem from the T ) and broad enough (the cross of the T ) to enable their possessors to explore the interfaces between their particular knowledge domain and various applications of that knowledge in particular products. It is the understanding and management of those interfaces that makes these skills especially critical to the firm's organizational capabilities (Leonard, 1995) .
UK Universities, however, are perceived as having deficiencies in some of the practical training they offer. GlaxoSmithKline has started to shift overseas in terms of recruitment for UK-based research groups, due to the lack of laboratory experience. This is shown by a trend to recruitment from the rest of the EU and even the USA.
Evidence from AstraZeneca indicates that technological knowledge can be transferred informally through information flows and knowledge sharing within professional networks. Sharing knowledge through professional networks involves a much wider process that involves social and cognitive structures which can assimilate information and put it into a wider innovation contact, allowing actions and learning to be undertaken from it. Collaborations, however, do not necessarily create the network. Networks may be created first through professional societies, attendance at meetings and by the background of the scientist at AstraZeneca. The critical question is how effectively the pharmaceutical firm is using its professional networks to share and create knowledge to gain competitive advantage, and what are the specific organisational competences that need to be developed to leverage tacit knowledge (Baumard, 1999; Scharmer, 2000) .
Conclusion
The literature review and the evidence presented in this paper has illustrated that universities are undergoing continuous change in their knowledge base, culture, structures, and strategic orientation. The traditionally view of universities as supplier of graduates and developments in fundamental research on the one hand; and firms as responsible for their own product development within a short term perspective on the other, has been challenged. These separate roles had been underpinned by the linear "Mode one" for knowledge production. A new approach, which has become more apparent in the last decade, is characterised by research universities forging stronger and more dynamic links with industry (Faulkner, 1995; Faulkner & Senker, 1995; Martin & Salter, 1996) . University-Industry research collaboration underpinned by this new approach has resulted in tangible benefits for the UK Biotech Industry in terms of novel and profitable discoveries. This new approach can be characterized by the emergence of distinguishable interorganisational processes for knowledge transfer, such as the creation of new spin out companies, production of skilled postgraduates, development of new instrumentation and methodologies, strengthening of technological problem-solving, and dissemination of knowledge and people through the establishment of professional networks. The management of scientific and technological knowledge, therefore, will not be effective without promoting these inter-organisational processes, and supporting organisational capabilities.
The resulting knowledge transfer scenario can be described as a win-win situation for both academia and industry, which is characterised by a proactive transition from a supply-based scenario to an entrepreneurialoriented model. The new approach is creating a much more proactive attitude to innovation and exploitation within academics and industrial collaborators. This new approach is enabling UK Universities to better respond to industry needs and market opportunities, within a new research environment characterized by co-innovation strategies and increased cooperation, particularly in the Biotechnology Sector (Bossink, 2002; Salazar et al., 2003a and 2003b; Santos, 2003; Spencer, 2003) .
A limitation of the research design may that the findings cannot be statistically generalized to comparable cases. Another limitation of the research design is that the exploratory case studies focus on the different type of exchange and processes, and the competences required to successfully manage those exchanges, rather than the more traditional performance and output measures which are more easily comparable.
